Heart Failure Pharmacotherapy Across the TAVR Continuum

Takayuki Onishi

doi:10.1016/j.cardfail.2026.06.011

Heart Failure Pharmacotherapy Across the TAVR Continuum

2026-07-04

0

PRE

AI

T

Takayuki Onishi

G

Gilbert H.L. Tang

A

Andy Moyal

K

Krishna Santosh

S

Sri Swaminathan

J

Johanna Contreras

N

Noah Moss

S

Sahil Khera

A

Amit Hooda

G

George Dangas

A

Annapoorna S. Kini

S

Samin K. Sharma

S

Sunny Goel *

DOI：10.1016/j.cardfail.2026.06.011

Original

Original request for help

Save

Abstract

En 中文

Take Home Illustration. Heart Failure Pharmacotherapy Across the TAVR Continuum. GDMT recommendations across the pre-, peri-, and post-procedural phases of TAVR. The recommendations are based on available evidence for each drug class regarding safety, efficacy, and impact on clinical outcomes. BB = beta blocker; HF = heart failure; GDMT = guideline directed medical therapy; HFpEF = heart failure with preserved ejection fraction; HFrEF = heart failure with reduced ejection fraction; MRA = mineralocorticoid receptor antagonist; RASi = renin angiotensin system inhibitor; SGLT2i = sodium glucose transporter 2 inhibitor; TAVR = transcatheter aortic valve replacement. Download: Download high-res image (251KB) Download: Download full-size image

Heart Failure Pharmacotherapy Across the TAVR Continuum

Abstract

Journal

Organization

Cited Papers

Citing Papers